Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis?
- 4 January 2018
- journal article
- letter
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 51 (1) , 1701737
Abstract
Cases of radiation pneumonitis developed after concomitant checkpoint inhibitors and lung SBRT: a matter of concern?http://ow.ly/k78q30g1qDJKeywords
This publication has 9 references indexed in Scilit:
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung CancerNew England Journal of Medicine, 2017
- Immune checkpoint inhibitor-associated interstitial lung diseases: some progress but still many issuesEuropean Respiratory Journal, 2017
- Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patientsEuropean Respiratory Journal, 2017
- Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trialThe Lancet Oncology, 2017
- Immunological Aspect of Radiation-Induced Pneumonitis, Current Treatment Strategies, and Future ProspectsFrontiers in Immunology, 2017
- Effects of CTGF Blockade on Attenuation and Reversal of Radiation-Induced Pulmonary FibrosisJNCI: Journal of the National Cancer Institute, 2017
- Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 StudiesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2016
- Role of Local Radiation Therapy in Cancer ImmunotherapyJAMA Oncology, 2015
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancerNature, 2015